On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev

Submitted by admin on February 13, 2023 - 10:29am
Source: 
Fierce Biotech
News Tags: 
Corbus Pharmaceuticals
Seagen
Padcev
CRB-701
oncology
Headline: 
On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev
snippet: 

Corbus Pharmaceuticals is mounting a David vs. Goliath battle against Seagen, spending $7.5 million of its dwindling cash reserves on a challenger to the nectin-4 antibody-drug conjugate (ADC) Padcev.

Do Not Allow Advertisers to Use My Personal information